Upload your bloodwork, genetics, and wearable data. Refract's AI cross-references all of it, then builds you a precise, personalized plan for your supplements, diet, and training. Not generic advice. Your biology. Your plan.
The AI reads your data across every layer, then builds specific, ranked, actionable output for four things: what to take, what to eat, how to train, and what to track next.
Not "consider magnesium." Your specific supplements, exact doses, optimal forms, optimal timing, and which of your current supplements are interfering with each other, or are the wrong form for your genetics.
Specific dietary changes based on your labs, genetics, and wearable patterns, not generic macros. Your APOE genotype changes how saturated fat affects your LDL. Your MTNR1B variant changes what time you should stop eating.
Your training load cross-referenced with your labs, HRV trends, and genetics. Are you recovering? Is your zone 2 distribution right? Are your recovery modalities helping or actively working against your goals?
Sequenced interventions with specific retesting milestones. What to change first, what to add at month two, what to retest at month three, and what success looks like in the numbers.
Medications, supplements with timing, recovery therapies, training load. This is what makes your labs interpretable. Takes 15–20 minutes.
Lab PDFs from any lab, 23andMe raw file, Apple Health export, Whoop/Oura/Garmin data, CGM export, Withings or smart scale CSV, Cronometer or MyFitnessPal nutrition export. Any combination, more layers means higher confidence output.
Every marker is checked against every other relevant marker, your genetics, your context, your therapy history, and your wearable trends. Confounders are flagged automatically.
Supplement protocol, dietary adjustments, training optimizations, and a six-month roadmap, all specific to your biology, not population averages.
Quarterly uploads track your markers over time. See which interventions are working in the numbers. The plan updates as your data does.
The more data layers you provide, the higher the confidence score and the more specific the plan. Start with labs, add layers over time.
Any PDF lab report from any lab. Standard panels or advanced markers, all parsed and interpreted against optimal ranges, not just reference ranges.
23andMe or AncestryDNA raw data file. 200+ genes screened for clinically validated variants. MTHFR, APOE, DIO2, COMT, FKBP5, ACTN3, and many more.
HRV trends, sleep staging, training load, heart rate zones, recovery scores. All major platforms supported with device-specific interpretation rules.
Continuous glucose monitor exports. Overnight patterns, postprandial spikes, reactive hypoglycemia, correlated with your genetics, sleep, and meal timing.
Smart scale exports tracking weight, body fat %, muscle mass, visceral fat, and bone density over time. Longitudinal trends cross-referenced with labs, training load, and nutrition, because a number on a scale means nothing without context.
Detailed dietary logs cross-referenced against your labs and genetics. Not generic macros, your actual micronutrient intake mapped against your deficiencies. Why is your ferritin low when you eat red meat? Why is your B12 borderline when you supplement? The answer is usually in the food log.
Most analyses look at one system at a time. Refract analyzes twelve overlapping systems together, then maps how they affect each other. Genetics modify how lab values should be read. Lifestyle modifies how genetics express. Wearables reveal what bloodwork misses. The cross-tier synthesis is where the insight lives.
Your report isn't a list of abnormal values. It's a structured document with seven sections, each doing distinct work. Read it once. Reference it for the next decade.
Specific. Layered. Direct. No hedging. No generic advice. This is what your plan looks like.
Your Lp(a) is 94 nmol/L, above the threshold where cardiovascular risk is independently elevated regardless of other lipid values. Your standard cholesterol panel looks unremarkable. This is exactly why Lp(a) is commonly missed. Simultaneously, your homocysteine at 13.2 μmol/L is elevated, and these two markers compound each other's risk. Your MTHFR compound heterozygous status is the driver: your methylation cycle is impaired and it is showing in the labs. Homocysteine is modifiable with the right B vitamin forms. The Lp(a) is largely genetic and requires a direct cardiology conversation.
You are taking a B-complex containing 400mcg folic acid. With your MTHFR C677T compound heterozygous genotype, folic acid does not convert properly and actively blocks the methylfolate receptor, making your methylation problem worse, not better. Switch to 5-MTHF (methylfolate) 400mcg immediately. Your B-complex also contains cyanocobalamin: switch to methylcobalamin 1000mcg sublingual. These are not subtle upgrades. They are the correct forms for your specific genetics.
Your TSH is 1.8 mIU/L. Your doctor flagged nothing. But your Free T3 is 2.6 pg/mL and your DIO2 Thr92Ala genotype is TT homozygous, meaning T4 to T3 conversion is impaired in brain and peripheral tissue. Your thyroid is producing hormone. The conversion is failing. Standard thyroid testing is designed to miss exactly this. Selenium (you are getting none in your current stack) is a required cofactor for this conversion. Your ferritin at 31 is also limiting thyroid peroxidase activity. Both are addressable before any medication conversation.
Your MTNR1B G allele impairs nighttime insulin secretion. Your CGM shows overnight glucose consistently at 95 to 102 mg/dL. Your last meal averages 9:40pm. These three data points form a complete picture: late eating is causing a glucose spike during high melatonin, suppressing insulin secretion, and the elevated overnight glucose is showing up as reduced deep sleep (average 44 min on high-glucose nights vs. 71 min on low-glucose nights in your Whoop data). Moving your last meal to 7:00pm is a single change that addresses all three simultaneously.
Your intake shows cold water immersion within 30 to 60 minutes post-lifting, 4 days per week. Immediate post-resistance cold immersion blunts the mTOR and satellite cell signaling required for hypertrophy. This is well-established in the published literature. The anti-inflammatory response you are trying to accelerate is the same response that drives muscle adaptation. Move cold immersion to off days, or minimum 4 to 6 hours after strength sessions. This change costs nothing and directly addresses a likely contributor to stalled strength progress.
Your VO2max trend over 6 months is up 11%. Your fasting glucose has held in 75 to 82 mg/dL despite progressive training intensity. Your sleep efficiency averages 92%. Cardiac drift in your Whoop data shows declining heart rate at the same workload over time, a clean signal of aerobic adaptation. Whatever the cardio plus zone 2 plus strength split looks like, it is working. The priority findings above describe specific bottlenecks. They do not describe a broken engine. The foundational engine is performing well. Maintain.
The most striking thing in your data is not any single finding. It is that three of the priority findings above share a single root cause: your methylation cycle. With your MTHFR C677T + COMT V158M genotype, the cycle is impaired. Address methylation correctly and four downstream findings improve in parallel.
Finding 1 (Lp(a) + homocysteine compounding): homocysteine drops, removing the methylation contribution to cardiovascular risk.
Finding 3 (T4→T3 conversion): methylation drives DIO2 expression. Free T3 rises with the cycle restored.
Finding 4 (overnight glucose disruption): melatonin and methylation share substrate pathways. Sleep architecture stabilizes.
Findings 5 + 6: training adaptation and aerobic gains compound when methylation supports neurotransmitter and cofactor synthesis.
One root cause. Four downstream findings. This is what cross-tier analysis catches that single-system review cannot.
| Supplement | Form | Dose | Timing | Why |
|---|---|---|---|---|
| B-Complex | 5-MTHF + methyl-B12 | 400mcg / 1000mcg | AM, with food | MTHFR genotype |
| Vitamin D | D3 + K2 (MK-7) | 5000 IU / 100mcg | AM, with fat | Co-factor pairing |
| Magnesium | Glycinate | 400mg | PM, 60 min before bed | Sleep + insulin |
| Selenium | Selenomethionine | 200mcg | AM | T4→T3 cofactor |
| Iron | Bisglycinate | 25mg | PM, 2hr from coffee/tea | Repletion to ferritin 70+ |
| ✗ Folic acid | · | · | STOP | Wrong form for genotype |
| ✗ Cyanocobalamin | · | · | STOP | Wrong form for genotype |
| Marker | Current | Target | Retest at |
|---|---|---|---|
| Homocysteine | 13.2 μmol/L High | < 7.0 Optimal | 90 days |
| Free T3 | 2.6 pg/mL Low | ≥ 3.2 Optimal | 90 days |
| Ferritin | 31 ng/mL Low | 70 to 100 Optimal | 90 days |
| hsCRP | 1.4 mg/L Mid | < 1.0 Optimal | 90 days |
| Vitamin D | 28 ng/mL Low | 50 to 80 Optimal | 90 days |
| Lp(a) | 94 nmol/L | Specialty discussion | One-time, then per cardiology |
Most analyses read a lab value and treat it as truth. Refract treats every lab value as a question: was this real, or was it an artifact of timing, supplements, infusions, or the day you happened to draw blood? Here are eight of the sixty-four confounders the intake system catches before a single finding is generated.
Most prospects ask how this differs from what they already have. The honest answer: Refract is doing different work than any of the alternatives, at a depth that none of them deliver.
| Capability | Annual Physical | Function Health | Concierge Clinic | Refract |
|---|---|---|---|---|
| Cross-tier integration Labs + genetics + wearables + lifestyle, read as one |
Labs only | Labs + clinical | All four layers | |
| Genetics-aware interpretation 200+ genes screened, MTHFR, COMT, DIO2, etc. |
Sometimes | Always | ||
| Confounder detection IV therapy, cycle phase, supplement-genotype mismatch |
Provider-dependent | 64+ catches | ||
| Written narrative report Read once, reference for years |
Visit notes | Dashboard only | Sometimes | 20+ pages |
| Specific protocols Forms, doses, timing, interactions |
Generic | |||
| Operator-level work A specific human, not a rotating staff |
Sometimes | Always | ||
| 6-month follow-up included Marker response tracked across interventions |
Self-tracked | Add-on cost | Standard | |
| Typical price | Insurance copay | $499/year | $3,000 to $7,500 | $397 early access |
Tell me what data you have. I'll be in touch within 24 hours to walk through what your report would look like and get you started. The early-access cohort is genuinely small.
Start with a single analysis. Add data layers as you collect them. Upgrade to monitoring when you're ready to track change over time.
Labs + genetics + wearables + body composition + nutrition. Full cross-reference. This is the analysis that changes how you understand your body.
Quarterly re-analysis. See what's changed, what your interventions did to the numbers, and what to do next.
No genetics or wearables yet. Start with your bloodwork, the most direct window into what's actually happening.
No marketing language. The questions sophisticated friends actually ask before saying yes.
No. Refract is health data analysis, not a medical practice. The report is designed to help you have better conversations with the doctors you already see, not to replace them. Every report includes a "Questions for Your Physician" document with the highest-leverage things to bring up at your next visit.
That said, the analysis is genuinely substantive. Most clients come back saying their physician engaged with the report seriously, and that the report changed what they got tested or treated for next.
Refract works at any data depth. The Confidence Score (Section 1 of every report) tells you exactly what was analyzed and how that affects the conclusions. With just labs, you get a sharp lab analysis. Add genetics, you unlock cross-reference. Add wearable data, you unlock pattern recognition. Add CGM and nutrition, you unlock the full integrated picture.
Most clients start with what they have and add layers over time. The follow-up report cycle is built for exactly this.
Function Health is a lab subscription with a dashboard. It tells you which markers are flagged. It does not integrate genetics, wearables, lifestyle, or supplement context. It does not produce a written narrative report. Different product.
10X and concierge clinics deliver clinical workups inside a medical practice model. They do excellent work and they cost $5,000+ for the kind of depth Refract delivers. Refract is the analysis layer, not the clinical practice. You can use Refract alongside any of these. Many clients do.
The piece nobody else does: cross-tier integration with genetics-aware interpretation and confounder detection, in a single written document, by a single operator.
Helpful but not required. Without genetics, you still get the full lab + wearable + lifestyle integration. With genetics, you unlock the deepest layer: variants like MTHFR, COMT, DIO2, MTNR1B that change how lab values should be read and what protocols actually work for you.
If you do not have raw genetic data yet, a 23andMe kit is around $99 and takes 4 to 6 weeks to process. Most clients order it during the intake process and we add the genetic overlay in the follow-up report.
Your data is yours. Refract analyzes it under a written consent and data handling agreement that is shared before you upload anything. Data is not sold, not shared with insurance, not used for any purpose other than producing your report and your follow-up reports. You can request deletion of all your data at any time.
Refract uses AI as the analysis engine. The intake explicitly discloses what AI processes what data. The full consent document is sent before you begin.
Matt Wilson, founder of Refract. Every report is run, reviewed, and signed off on personally. AI is the analysis substrate. The methodology, editorial judgment, and final report are operator-level work. There is no rotating staff, no offshore analyst, no template.
This is also why early access is genuinely limited. Manual delivery has a real ceiling per month. The first cohort gets the deepest engagement.
Most clients retest the priority markers at 90 days and come back for a follow-up analysis at 6 months. The follow-up report is included with early access. It tracks marker response to each intervention and recalibrates the protocol. This is where the compounding value of Refract lives. The first report tells you what to change. The follow-up tells you what worked, what did not, and what is next.
Early Access
Tell me what data you have. I'll be in touch within 24 hours to walk you through what your report would look like and get you started.
No spam. No sharing. Limited spots. $397 one-time, locked in for early access members.